Tag: Salarius Pharmaceuticals


Salarius Pharmaceuticals Inc (NASDAQ: SLRX) Embarks On A New Trial To Study Seclidemstat

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) embark on a clinical trial that seeks to investigate a novel lysine-specific demethylase 1 (LSD1) inhibitor called seclidemstat. This biopharmaceutical company has, over the years, focused n the development of working medicines to help out persons struggling with solid tumors,  pediatric cancers, and other cancers. Conducting […]


Salarius Pharmaceuticals Inc (NASDAQ: SLRX) in the Green Zone Over Key Clinical Findings

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) exited yesterday at $1.22, up 0.83%. SLRX has been in the green zone for a long time, and here’s why.  Investors responding well to key findings from seclidemstat’s clinical research SLRX, the clinical-stage biopharmaceutical company, is known for developing treatments for cancers, solid tumors, and […]